Johnson & Johnson

Johnson & Johnson

Company operating in consumer, pharmaceutical and medical device categories. Johnson & Johnson is engaged in research and development, manufacture and sale of healthcare products.

Johnson & Johnson is a company operating in consumer, pharmaceutical and medical device categories. Johnson & Johnson is engaged in research and development, manufacture and sale of healthcare products. The consumer segment includes baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care. The pharmaceutical segment includes immunology, infectious disease, neuroscience, oncology, cardiovascular disease and metabolic disease. Their medical device segment includes orthopedic, surgery, cardiovascular, diabetes care and vision care. J&J has research facilities in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

COVID-19

Johnson & Johnson teamed up with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against the new coronavirus strain responsible for the COVID-19 outbreak. J&J will use its AdVac viral vector and PER.C6 cell line for coronavirus vaccine development. These are the same technologies used to develop an Ebola vaccine that is in testing in Africa, prophylactics against Zika, HIV and respiratory syncytial virus. J&J’s Janssen unit and BARDA plan to co-fund research and development of the vaccine and make their resources available. J&J donated bottles of its HIV drug darunavir/cobicistat, marketed under the brand name Prezcobix, to researchers in China investigating it as a potential treatment for the new coronavirus. Other J&J antiviral drugs on the market or in its pipeline will be included in research to test if they could help the fight the novel coronavirus strain causing the COVID-19 outbreak.

Timeline

February 12, 2020

J&J allies with BARDA to accelerate coronavirus vaccine program

April 2, 2019

Johnson & Johnson acquires Auris Health.

Johnson & Johnson announced that its Ethicon biz completed $3.4 billion acquisition of robotic surgery dev Auris Health.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Johnson & Johnson funding round, March 2003
3,000,000
March 31, 2003
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Chanel-Marie London

Investor

Gore Bolton

Investor

James Dickey

Investor

James Haefele

Investor

Joseph A Bianco III

Investor

Josh Bolinger

Advisor

Kim Michael Janas, MBA

Advisor

Mohamed El Beltagi

Investor

Orly Glick

Advisor

Sushil Pratap Bharati

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.